Vaxdyn has expertise and know-how regarding methods for testing and optimizing novel compounds for the treatment and prevention of infections caused by multidrug resistant bacteria that are currently being exploited internally for the development of Vaxdyn’s product lines. These methods and techniques include in vitro testing and in vivo studies for the preclinical development of new antibiotics. Also our experience allow us to reprofile authorized antibiotic to increase their clinical indications.

In vitro antimicrobial susceptibility testing of novel compounds on collections of multidrug resistant pathogens:

  • MIC, MIC50, MIC90 values for Acinetobacter baumanniiPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliStaphylococcus spp.
  • Time kill curves.
  • Synergy studies.

In vivo efficacy studies of novel anti-infection compounds in murine models.

  • Pharmacokinetic and pharmacodynamics studies.
  • Survival data.
  • Serum cytokine levels.
  • Tissue bacteria loads.
  • Several animal model systems are avalaible using any of the above pathogens.

Our experience allow us to design any other murine models adjusted for the study of new antimicrobials.

In vivo toxicity testing of novel compounds:

  • LD0, LD50, LD100 values.
  • Serum cytokine profiles.